| 000 | 01779 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513152732.0 | ||
| 264 | 0 | _c19990524 | |
| 008 | 199905s 0 0 eng d | ||
| 022 | _a0952-3278 | ||
| 024 | 7 |
_a10.1016/s0952-3278(98)90052-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLora, M | |
| 245 | 0 | 0 |
_aSystematic pharmacological approach to the characterization of NSAIDs. _h[electronic resource] |
| 260 |
_bProstaglandins, leukotrienes, and essential fatty acids _cJul 1998 |
||
| 300 |
_a55-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology |
| 650 | 0 | 4 |
_aAspirin _xpharmacology |
| 650 | 0 | 4 | _aCOS Cells |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aCyclooxygenase 1 |
| 650 | 0 | 4 | _aCyclooxygenase 2 |
| 650 | 0 | 4 | _aCyclooxygenase 2 Inhibitors |
| 650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aEnzyme Activation _xdrug effects |
| 650 | 0 | 4 | _aGenetic Vectors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndomethacin _xpharmacology |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aIsoenzymes _xdrug effects |
| 650 | 0 | 4 |
_aMefenamic Acid _xpharmacology |
| 650 | 0 | 4 | _aMembrane Proteins |
| 650 | 0 | 4 |
_aNitrobenzenes _xpharmacology |
| 650 | 0 | 4 |
_aProstaglandin-Endoperoxide Synthases _xgenetics |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTransfection _xmethods |
| 700 | 1 | _aDenault, J B | |
| 700 | 1 | _aLeduc, R | |
| 700 | 1 | _ade Brum-Fernandes, A J | |
| 773 | 0 |
_tProstaglandins, leukotrienes, and essential fatty acids _gvol. 59 _gno. 1 _gp. 55-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0952-3278(98)90052-7 _zAvailable from publisher's website |
| 999 |
_c9723094 _d9723094 |
||